101 FRAIL-AF RANDOMISED CONTROLLED TRIAL: RATIONALE AND DESIGN 19. Baitar A, Van Fraeyenhove F, Vandebroek A, De Droogh E, Galdermans D, Mebis J, et al. Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. J Geriatr Oncol. 2013;4(1):32–8. 20. Mant JW, Richards SH, Hobbs FR, Fitzmaurice D, Lip GY, Murray E, et al. Protocol for Birmingham atrial fibrillation treatment of the aged study (BAFTA): A randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population. BMC Cardiovasc Disord. 2003;3:9. 21. Kooistra HA, Calf AH, Piersma-Wichers M, Kluin-Nelemans HC, Izaks GJ, Veeger NJ, et al. Risk of bleeding and thrombosis in patients 70 Years or older using vitamin K antagonists. JAMA Intern Med. 2016;176(8):1176–83. 22. Boehringer Ingelheim Pharma GmbH & Co. KG. Samenvatting van de productkenmerken van dabigatran. [Internet]. [cited 2018 Aug 1]. Available from: http://www.ema.europa. eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/000262/ WC500027361.pdf 23. Bayer Pharma AG and Bayer HealthCare Manufacturing S.r.l. Samenvatting van de productkernmerken van rivaroxaban. [Internet]. [cited 2018 Aug 1]. Available from: http:// www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/ human/000944/WC500057108.pdf 24. Bristol-Myers Squibb S.r.l. and Phizer Manufacturing Deutschland GmbH. Samenvatting van de productkenmerken van apixaban. [Internet]. [cited 2018 Aug 1]. Available from: http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/ human/002148/WC500107728.pdf 25. Daiichi Sankyo Europa GmbH. Samenvatting van de productkenmerken van edoxaban. [Internet]. [cited 2018 Aug 1]. Available from: http://www.ema.europa.eu/docs/nl_NL/ document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf 26. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005;3(4):692–4. 27. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. 28. Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanters T, Tan S. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 2015;1–24. 29. World Medical Association. WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. 2013. 30. Wet medisch-wetenschappelijk onderzoek met mensen. [Internet]. 1998 [cited 2018 Aug 1]. Available from: https://wetten.overheid.nl/BWBR0009408/2018-08-01 31. van Miert JHA, Kooistra HAM, Veeger NJGM, Westerterp A, Piersma-Wichers M, Meijer K. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: A randomised controlled trial (GAInN). Br J Haematol. 2019;186(3). 32. Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123(7):638-645.e4. 33. Attaya S, Bornstein T, Ronquillo N, Volgman R, Braun L, Trohman R, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther. 2012;19(6):432–5. 34. Boom M, Berghuis E, Nieuwkerk P, Pinedo S, Büller H. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist? Neth J Med. 2015;73(8):368–72. 6
RkJQdWJsaXNoZXIy MTk4NDMw